Related references
Note: Only part of the references are listed.Eltrombopag added to immunosuppression for children with treatment-naive severe aplastic anaemia
Emma M. Groarke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia
Husam Qanash et al.
CELLS (2021)
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Xing Fan et al.
BLOOD ADVANCES (2020)
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
Thomas Winkler et al.
BLOOD (2019)
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
Jong Wook Lee et al.
LANCET HAEMATOLOGY (2019)
Eltrombopag mobilizes iron in patients with aplastic anemia
Zhen Zhao et al.
BLOOD (2018)
Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag
Yun-Ruei Kao et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
Francesca Punzo et al.
PLOS ONE (2018)
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study
Emanuela Messa et al.
LEUKEMIA & LYMPHOMA (2017)
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Danielle M. Townsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inherited bone marrow failure syndromes: considerations pre- and posttransplant
Blanche P. Alter
BLOOD (2017)
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Evangelia Vlachodimitropoulou et al.
BLOOD (2017)
Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia
Michele P. Lambert et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
John D. Grainger et al.
LANCET (2015)
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study
James B. Bussel et al.
LANCET HAEMATOLOGY (2015)
Evolution of iron burden in acquired aplastic anemia: a cohort study of more than 3-year follow-up
Peng Jin et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Effects of Iron Overload on the Bone Marrow Microenvironment in Mice
Yuchen Zhang et al.
PLOS ONE (2015)
Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia
Phillip Scheinberg et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution
Phillip Scheinberg et al.
BLOOD (2014)
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
Emanuele Angelucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia
Sung-Eun Lee et al.
ACTA HAEMATOLOGICA (2013)
Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients
Wenyi Lu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study
Jong Wook Lee et al.
HAEMATOLOGICA (2013)
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
Julia Hartmann et al.
LEUKEMIA RESEARCH (2013)
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia
Phillip Scheinberg et al.
BLOOD (2012)
Prognostic impact of iron parameters in patients undergoing allo-SCT
G. N. Bazuave et al.
BONE MARROW TRANSPLANTATION (2012)
The effect of iron overload and chelation on erythroid differentiation
Kazuki Taoka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Matthew J. Olnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng et al.
LANCET (2011)
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
Roberto Guariglia et al.
LEUKEMIA RESEARCH (2011)
Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
Phillip Scheinberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
Esther Natalie Oliva et al.
TRANSFUSION (2010)
Effects of Food and Antacids on the Pharmacokinetics of Eltrombopag in Healthy Adult Subjects: Two Single-Dose, Open-Label, Randomized-Sequence, Crossover Studies
Daphne D. Williams et al.
CLINICAL THERAPEUTICS (2009)
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
Phillip Scheinberg et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
James B. Bussel et al.
LANCET (2009)
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
E. Messa et al.
ACTA HAEMATOLOGICA (2008)
Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
Cheng E. Chee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
M. Cazzola et al.
Hematology-American Society of Hematology Education Program (2008)
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil
P Scheinberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Antithymocyte globulin and cyclosporine for severe aplastic anemia - Association between hematologic response and long-term outcome
S Rosenfeld et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
